Loading...
Loading...
Browse all stories on DeepNewz
VisitFirst Clinical Application of eePASSIGE System?
Cystic Fibrosis • 25%
Sickle Cell Anemia • 25%
Duchenne Muscular Dystrophy • 25%
Hemophilia • 25%
Official announcements from research institutions, clinical trial registrations, and peer-reviewed publications
New eePASSIGE System Enhances Gene Editing in Human Cells at Therapeutic Levels
Jun 10, 2024, 02:11 PM
A new gene-editing system called eePASSIGE, which combines evolved and engineered recombinases with prime editing, has been reported in Nature Biomedical Engineering. This system enables the efficient, precise, and targeted integration of large gene-sized DNA cargoes into the mammalian genome. The approach aims to insert or substitute gene-sized DNA segments in human cells at therapeutic levels, potentially paving the way for one-size-fits-all gene therapies for diseases such as cystic fibrosis. Researchers are discussing the distinctions between these approaches and their potential applications in genomic medicine.
View original story
Liver Disease • 25%
Cystic Fibrosis • 25%
Muscular Dystrophy • 25%
Hemophilia • 25%
Cancer • 25%
Alzheimer's Disease • 25%
Cystic Fibrosis • 25%
Sickle Cell Disease • 25%
Oncology • 25%
Neurodegenerative Diseases • 25%
Cardiovascular Diseases • 25%
Infectious Diseases • 25%
Transthyretin Amyloidosis • 25%
Sickle Cell Disease • 25%
Cystic Fibrosis • 25%
Muscular Dystrophy • 25%
Parkinson's Disease • 25%
Alzheimer's Disease • 25%
Multiple Sclerosis • 25%
Epilepsy • 25%
Cancer • 20%
Rare genetic disorders • 20%
Heart disease • 20%
Neurological disorders • 20%
Other • 20%
Mayo Clinic • 25%
Cleveland Clinic • 25%
Johns Hopkins Hospital • 25%
MD Anderson Cancer Center • 25%
No • 50%
Yes • 50%
Nobel Prize • 33%
Breakthrough Prize • 33%
Lasker Award • 33%